A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2012
At a glance
- Drugs SGI 1776 (Primary)
- Indications Leukaemia
- Focus Adverse reactions
- Sponsors Astex Pharmaceuticals
- 28 Nov 2011 Company added in the association field and additional lead trial center identified as reported by ClinicalTrials.gov.
- 18 Nov 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Nov 2010 New trial record